Skip to content
2000
Volume 21, Issue 4
  • ISSN: 1573-3947
  • E-ISSN: 1875-6301

Abstract

Chimeric Antigen Receptor T-cell (CAR-T) therapy has emerged as a ground-breaking approach in cancer treatment, offering new hope to patients with refractory or relapsed malignancies. By genetically modifying T lymphocytes, this potent method allows for the targeted eradication of infectious cells. The efficient production of CAR-T cells is essential for the effective use of these treatments to treat malignancies, as it affects not just the product's efficacy as well as safety but also its general availability to patients who require it. This article's primary goal is to provide a comprehensive overview of CAR-T therapy, encompassing its historical evolution, mechanistic insights, clinical applications, challenges, and future directions. By synthesizing existing literature and real-world evidence, this review seeks to elucidate the significance of CAR-T therapy in the landscape of cancer treatment and its potential to redefine the standard of care for patients with refractory or relapsed malignancies. The methodology involved a comprehensive literature search conducted using various databases, including PubMed, Google Scholar, and clinical trial registries such as ClinicalTrials.gov. The search strategy incorporated a combination of relevant keywords and Medical Subject Headings (MeSH) terms, including but not limited to “CAR-T therapy,” “chimeric antigen receptor T-cell therapy,” “cancer immunotherapy,” “clinical trials,” “pharmaceutical companies,” “regulatory approvals,” “pipeline molecules,” and “cancer types.” Boolean operators (AND, OR) were utilized to refine the search and capture relevant articles and studies. In addition to database searches, manual screening of reference lists from relevant review articles and primary studies was performed to identify additional relevant publications. The inclusion criteria encompassed original research articles, clinical trials, systematic reviews, meta-analyses, and regulatory documents related to CAR-T cell therapy and its applications in cancer treatment and the review included studies published in English between January 2010 and March 2024. Exclusion criteria comprised studies not relevant to the scope of the review, such as those focusing on non-CAR-T cell therapies or non-cancer-related topics. This review underscores the transformative potential of CAR-T therapy in cancer treatment, highlighting its efficacy, safety, and clinical relevance across various malignancies. By synthesizing findings from preclinical studies, clinical trials, and real-world data from patients, CAR-T therapy has consistently exhibited remarkable therapeutic outcomes. These include high response rates, durable remissions, and significant improvements in survival outcomes among patients with refractory or relapsed cancers. Additionally, the inclusion of practical research with big data from real patients further supports the robustness and applicability of CAR-T therapy in clinical practice. In conclusion, CAR-T therapy represents a paradigm shift in cancer treatment, offering new avenues for personalized and precision-driven oncology. By addressing current gaps, optimizing treatment protocols, and exploring novel strategies, CAR-T therapy holds immense promise in reshaping the landscape of oncology and providing hope to patients with advanced malignancies.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cctr/10.2174/0115733947320632240517093549
2024-05-22
2025-10-18

  • From This Site

    /content/journals/cctr/10.2174/0115733947320632240517093549
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. ZhangC. LiuJ. ZhongJ.F. ZhangX. Engineering CAR-T cells.Biomark. Res.2017512210.1186/s40364‑017‑0102‑y 28652918
     [Google Scholar]
  2. MausM.V. JuneC.H. Making better chimeric antigen receptors for adoptive t-cell therapy.Clin. Cancer Res.20162281875188410.1158/1078‑0432.CCR‑15‑1433 27084741
     [Google Scholar]
  3. LevineB.L. MiskinJ. WonnacottK. KeirC. Global manufacturing of CAR T cell therapy.Mol. Ther. Methods Clin. Dev.201749210110.1016/j.omtm.2016.12.006 28344995
     [Google Scholar]
  4. JuneC.H. O’ConnorR.S. KawalekarO.U. GhassemiS. MiloneM.C. CAR T cell immunotherapy for human cancer.Science201835963821361136510.1126/science.aar6711 29567707
     [Google Scholar]
  5. NeelapuS.S. LockeF.L. BartlettN.L. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-Cell lymphoma.N. Engl. J. Med.2017377262531254410.1056/NEJMoa1707447 29226797
     [Google Scholar]
  6. BonifantC.L. JacksonH.J. BrentjensR.J. CurranK.J. Toxicity and management in CAR T-cell therapy.Mol. Ther. Oncolytics201631601110.1038/mto.2016.11 27626062
     [Google Scholar]
  7. RafiqS. HackettC.S. BrentjensR.J. Engineering strategies to overcome the current roadblocks in CAR T cell therapy.Nat. Rev. Clin. Oncol.202017314716710.1038/s41571‑019‑0297‑y 31848460
     [Google Scholar]
  8. WangY. XuH. LiuT. Molecular pathway network of EFNB1 and ephrin-B1 in human cancers.J. Cancer202011226563657210.7150/jca.47189
     [Google Scholar]
  9. RajeN. BerdejaJ. LinY. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma.N. Engl. J. Med.2019380181726173710.1056/NEJMoa1817226 31042825
     [Google Scholar]
  10. LiuY. ChenX. HanW. ZhangY. Tisagenlecleucel: The first CAR-T cell therapy approved for the treatment of relapsed or refractory b-cell acute lymphoblastic leukemia.Drug Des. Devel. Ther.2021153931394110.2147/DDDT.S310413
     [Google Scholar]
  11. GauthierJ. TurtleC.J. Insights into cytokine release syndrome and neurotoxicity after CD19-specific CAR-T cell therapy.Curr. Res. Transl. Med.2018662505210.1016/j.retram.2018.03.003 29625831
     [Google Scholar]
  12. VormittagP. GunnR. GhorashianS. VeraitchF.S. A guide to manufacturing CAR T cell therapies.Curr. Opin. Biotechnol.20185316418110.1016/j.copbio.2018.01.025 29462761
     [Google Scholar]
  13. ScarfòI. MausM.V. Current approaches to increase CAR T cell potency in solid tumors: Targeting the tumor microenvironment.J. Immunother. Cancer2017512810.1186/s40425‑017‑0230‑9 28331617
     [Google Scholar]
  14. HanahanD. WeinbergR.A. Hallmarks of cancer: The next generation.Cell2011144564667410.1016/j.cell.2011.02.013 21376230
     [Google Scholar]
  15. SommermeyerD. HudecekM. KosasihP.L. Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo.Leukemia201630249250010.1038/leu.2015.247 26369987
     [Google Scholar]
  16. BaqueroP. DawsonA. MukhopadhyayA. Targeting quiescent leukemic stem cells using second-generation autologous CAR-T cells.Cancer Discov.202111923562367
     [Google Scholar]
  17. LeeK.L. BenzS.C. HicksM.J. The integrated pharmacodynamic analysis identifies two predictive biomarkers for cetuximab sensitivity in head and neck cancer.Mol. Cancer Ther.2021205886898
     [Google Scholar]
  18. ZucchettoA. CaldanaC. BenedettiD. Circulating microRNA expression profile identifies new biomarkers for the diagnosis of B-cell prolymphocytic leukemia.Blood Cells Mol. Dis.202188102514
     [Google Scholar]
  19. AhmadiankiaN. BahramiA.R. EbrahimiM. Cancer stem cells in solid tumors: A review.Eur. J. Pharmacol.2021899174072
     [Google Scholar]
  20. SolimandoA.G. Da ViàM.C. CiccoS. Leone P, Di Lernia G, Giannico D, Desantis V, Frassanito MA, Morizio A, Delgado Tascon J, Melaccio A, Saltarella I, Ranieri G, Ria R, Rasche L, Kortüm KM, Beilhack A, Racanelli V, Vacca A, Einsele H. High-risk multiple myeloma: integrated clinical and omics approach dissects the neoplastic clone and the tumor microenvironment.J. Clin. Med.201987997
     [Google Scholar]
  21. SulkowskiP.L. SundaramR.K. OeckS. Krebs cycle metabolites in cancer: Unraveling the molecular mechanisms underlying oncogenesis.Mol. Cancer202019115
     [Google Scholar]
  22. ScottM.L. ColemanM.M. KellyR.M. Modeling the effect of Epstein-Barr virus immune evasion on CD8+ T-cell surveillance during the early phase of infection.J. Gen. Virol.20201012157170
     [Google Scholar]
  23. SanchezJ. GelminiS. SantiniD. Basic principles of chemotherapy: Mechanisms of action.In: Cancer Targeted Drug Delivery: An Elusive Dream.Academic Press20204154
     [Google Scholar]
  24. SherD.J. AdelsteinD.J. BajajG.K. Brizel DM, Cohen EEW, Halthore A, Harrison LB, Lu C, Moeller BJ, Quon H, Rocco JW, Sturgis EM, Tishler RB, Trotti A, Waldron J, Eisbruch A. Radiation therapy for oropharyngeal squamous cell carcinoma: Executive summary of an ASTRO evidence-based clinical practice guideline.Pract. Radiat. Oncol.201774246253
     [Google Scholar]
  25. KronowitzS.J. KuererH.M. SmallK. Prospective randomized controlled trial of animation-assisted and traditional cohorts undergoing implant-based breast reconstruction.Ann. Surg. Oncol.20212841848186110.1245/s10434‑020‑09328‑3
     [Google Scholar]
  26. ZhouY. Rios PerezM.V. DeckerA.E. Extracellular matrix-associated prognostic genes highlight molecular subtypes and predict adjuvant chemotherapy benefit in non-metastatic colorectal cancer.Clin. Cancer Res.2021273857866
     [Google Scholar]
  27. SharmaP. Hu-LieskovanS. WargoJ.A. RibasA. Primary, adaptive, and acquired resistance to cancer immunotherapy.Cell2017168470772310.1016/j.cell.2017.01.017 28187290
     [Google Scholar]
  28. MengY. ChenC.W. YungM.M.H. DUOXA1-mediated ROS production promotes cisplatin resistance by activating the ATR-Chk1 pathway in ovarian cancer.Cancer Lett.2021497135148
     [Google Scholar]
  29. NogovaL. SequistL.V. Perez GarciaJ.M. Evaluation of BGJ398, a fibroblast growth factor receptor 1-3 kinase inhibitor, in patients with advanced solid tumors harboring genetic alterations in fibroblast growth factor receptors: Results of a global phase I, dose-escalation and dose-expansion study.J. Clin. Oncol.201735215716510.1200/JCO.2016.67.2048 27870574
     [Google Scholar]
  30. StathiasV. JermakowiczA.M. MaloofM.E. Drug and disease signature integration identifies collaborative networks in schizophrenia.NPJ Schizophr.2018418
     [Google Scholar]
  31. GhoshS CisarJS McDonnellME A reduced apoptotic ratio is a predictor of induction success in acute myeloid leukemia patients receiving venetoclax and azacitidine. Blood20211381425(Suppl. 1)
  32. Tissue Study in Patients Undergoing CAR-T Cell Therapy(CAR_21_01) (CAR_21_01). NCT04892433,2024
     [Google Scholar]
  33. Dual target CAR-T cell treatment for refractory systemic lupus erythematosus (SLE) patients NCT05858684,2023
     [Google Scholar]
  34. CAR T-cell therapy educational video trial. NCT04280133,2023
     [Google Scholar]
  35. CAR-T for r/r malignant tumors in children. NCT04691349,2021
     [Google Scholar]
  36. An evaluation trial about anti-claudin18.2 the specificity of chimeric antigen receptor T cells in the advanced gastric / esophagogastric junction adenocarcinoma and pancreatic cancer subjects. NCT05277987,2022
     [Google Scholar]
  37. Correlation between gut microbiota and clinical response to CAR-T treatment for hematological malignancies. NCT06041815,2022
     [Google Scholar]
  38. Study of therapeutic efficacy of anti-CD19 CAR-T cells in refractory systemic lupus erythematosus. NCT06222853,2024
     [Google Scholar]
  39. Multidimensional assessment of quality of life, social and professional life and care utilization in patients with diffuse large cell Bcell lymphoma treated with CAR-T Cells (QUALITOP CAR-T). NCT05532761,2022
     [Google Scholar]
  40. French register of patients with hemopathy eligible for CAR-T cell treatment (DESCAR-T). NCT04328298,2025
     [Google Scholar]
  41. CAR - γ δ T cells in the treatment of relapsed and refractory CD7 positive T cell-derived malignant tumors. NCT04702841,2021
     [Google Scholar]
  42. ePRO for the timely detection of side effects in cancer patients undergoing CAR T immunotherapy (CARTePRO). NCT05354973,2024
     [Google Scholar]
  43. Mesothelin/GPC3/GUCY2C-CAR-T cells against cancers. NCT05779917,2024
     [Google Scholar]
  44. Vaccine responsiveness after CAR-T cell therapy. NCT04410900,2025
     [Google Scholar]
  45. Looking at cognitive and brain changes in people with lymphoma receiving CAR-T therapy. NCT04107285,2024
     [Google Scholar]
  46. Restoration of immunity to vaccine preventable diseases after CART-T Cell Therapy (IMCAR). NCT06333275,2024
     [Google Scholar]
  47. Dasatinib plus anti-CD19/CD22 bispecific CAR-T cell therapy for elderly Ph-positive all patients. NCT05523661,2023
     [Google Scholar]
  48. Patient reported outcomes and patient education in cellular therapy patients. NCT04853277,2023
     [Google Scholar]
  49. CAR-T cell therapy in patients with hematological malignancies. NCT05390671,2022
     [Google Scholar]
  50. GD2/CD70 Bi-specific CAR-T cell therapy. NCT05438368,2022
     [Google Scholar]
  51. A study of DeepTag-GPRC5D targeted CAR-T cells therapy for refractory/relapsed multiple myeloma. NCT06084962,2023
     [Google Scholar]
  52. Car t cells with one or more interleukins. W.O. Patent 2019210293A12019
     [Google Scholar]
  53. Compositions and methods for CAR T cell therapy. U.S. Patent 11759480B2,2018
     [Google Scholar]
  54. CD7-CAR-T cell and preparation and application thereof. C.N. Patent 114144430B,2018
     [Google Scholar]
  55. Gene editing of CAR-T cells for the treatment of T-cell malignancies using chimeric antigen receptors. K.R. Patent 102546839B1,2017
     [Google Scholar]
  56. ZhangG. WangL. CuiH. Anti-melanoma activity of T cells redirected with a TCR-like chimeric antigen receptor.Sci. Rep.201441357110.1038/srep03571 24389689
     [Google Scholar]
  57. LiuX. JiangS. FangC. Affinity-Tuned ErbB2 or EGFR chimeric antigen receptor T cells exhibit an increased therapeutic index against tumors in mice.Cancer Res.201575173596360710.1158/0008‑5472.CAN‑15‑0159 26330166
     [Google Scholar]
  58. HudecekM. SommermeyerD. KosasihP.L. The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity.Cancer Immunol. Res.20153212513510.1158/2326‑6066.CIR‑14‑0127 25212991
     [Google Scholar]
  59. GuestR.D. HawkinsR.E. KirillovaN. The role of extracellular spacer regions in the optimal design of chimeric immune receptors: Evaluation of four different scFvs and antigens.J. Immunother.200528320321110.1097/01.cji.0000161397.96582.59 15838376
     [Google Scholar]
  60. WilkieS. PiccoG. FosterJ. Retargeting of human T cells to tumor-associated MUC1: The evolution of a chimeric antigen receptor.J. Immunol.200818074901490910.4049/jimmunol.180.7.4901 18354214
     [Google Scholar]
  61. HombachA. HombachA.A. AbkenH. Adoptive immunotherapy with genetically engineered T cells: modification of the IgG1 Fc ‘spacer’ domain in the extracellular moiety of chimeric antigen receptors avoids ‘off-target’ activation and unintended initiation of an innate immune response.Gene Ther.201017101206121310.1038/gt.2010.91 20555360
     [Google Scholar]
  62. AlmåsbakH. WalsengE. KristianA. Inclusion of an IgG1-Fc spacer abrogates efficacy of CD19 CAR T cells in a xenograft mouse model.Gene Ther.201522539140310.1038/gt.2015.4 25652098
     [Google Scholar]
  63. BridgemanJ.S. HawkinsR.E. BagleyS. BlaylockM. HollandM. GilhamD.E. The optimal antigen response of chimeric antigen receptors harboring the CD3zeta transmembrane domain is dependent upon incorporation of the receptor into the endogenous TCR/CD3 complex.J. Immunol.2010184126938694910.4049/jimmunol.0901766 20483753
     [Google Scholar]
  64. DottiG. GottschalkS. SavoldoB. BrennerM.K. Design and development of therapies using chimeric antigen receptor‐expressing T cells.Immunol. Rev.2014257110712610.1111/imr.12131 24329793
     [Google Scholar]
  65. AlabanzaL. PeguesM. GeldresC. Function of novel anti-CD19 chimeric antigen receptors with human variable regions is affected by hinge and transmembrane domains.Mol. Ther.201725112452246510.1016/j.ymthe.2017.07.013 28807568
     [Google Scholar]
  66. BrentjensR.J. LatoucheJ.B. SantosE. Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15.Nat. Med.20039327928610.1038/nm827 12579196
     [Google Scholar]
  67. ZhongX.S. MatsushitaM. PlotkinJ. RiviereI. SadelainM. Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl-XL activation and CD8+ T cell-mediated tumor eradication.Mol. Ther.201018241342010.1038/mt.2009.210 19773745
     [Google Scholar]
  68. Abate-DagaD. LagisettyK.H. TranE. A novel chimeric antigen receptor against prostate stem cell antigen mediates tumor destruction in a humanized mouse model of pancreatic cancer.Hum. Gene Ther.201425121003101210.1089/hum.2013.209 24694017
     [Google Scholar]
  69. MiloneM.C. FishJ.D. CarpenitoC. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo.Mol. Ther.20091781453146410.1038/mt.2009.83 19384291
     [Google Scholar]
  70. MackensenA. MüllerF. MougiakakosD. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus.Nat. Med.202228102124213210.1038/s41591‑022‑02017‑5 36109639
     [Google Scholar]
  71. Yescarta® CAR T-cell therapy demonstrates consistent survival outcomes and safety in real-world setting regardless of race and ethnicity.Available from: https://www.businesswire.com/news/home/20220603005447/en/
  72. Yescarta® is first CAR T-cell therapy to report five-year survival data from pivotal study showing durable long-term survival in patients with refractory large B-cell lymphoma.Available from: https://www.businesswire.com/news/home/20211211005050/en/
  73. GoldenD. Kymriah’s 5-year survival data shows promise of CAR T-cell therapy.Available from: https://acgtfoundation.org/news/kymriah-survival-data-shows-promise-of-car-t-cell-therapy/
  74. New analyses of kite's tecartus® CAR T-cell therapy provide additional evidence supporting overall survival and durability of response. Available from: https://www.businesswire.com/news/home/20221212005230/en/
  75. NaveO. ShorY. BarR. SegalE.E. SigronM. A new treatment for breast cancer using a combination of two drugs: AZD9496 and palbociclib.Sci. Rep.2024141130710.1038/s41598‑023‑48305‑z 38225243
     [Google Scholar]
  76. HuC. LiuM. LiY. Recent advances and future perspectives of CAR-T cell therapy in head and neck cancer.Front. Immunol.202314121371610.3389/fimmu.2023.1213716 37457699
     [Google Scholar]
/content/journals/cctr/10.2174/0115733947320632240517093549
Loading
Advancements in CAR-T Therapy: A Comprehensive Review
Curr Cancer Ther Rev 21, 433 (2025); https://doi.org/10.2174/0115733947320632240517093549
/content/journals/cctr/10.2174/0115733947320632240517093549
/content/journals/cctr/10.2174/0115733947320632240517093549
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): cancer treatment; CAR-T therapy; chimeric antigen receptors; immunotherapy; pipeline molecules; radiation therapy

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test